Advanced Search


Study ID Status Title Patient Level Data
115649 Completed Immunogenicity and safety study of GSK Biologicals’ Priorix vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s measles-mumps-rubella (MMR) vaccine when both are given on a 2-dose schedule to healthy children in their 2nd year of life
115650 Completed Safety and immunogenicity study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine, in healthy children 12 to 15 months of age
115658 Completed A randomised, double-blind, placebo controlled, inhaled single escalating and repeat dose study using an aqueous droplet inhaler to investigate the safety, tolerability and pharmacokinetics of GSK2339345. Study Listed on
115661 Completed A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in theMEA115588 or MEA115575 trials Study Listed on
115666 Completed MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial
115676 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects with Severe Renal Impairment Study Listed on
115677 Completed A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects Study Listed on
115678 Completed An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects Study Listed on
115679 Completed An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848). Study Listed on
115682 Completed WEUSKOP5522: Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761
115696 Completed An Adaptive, Two part, Two period, Single Sequence, Drug Interaction Study between Dolutegravir 50 mg and Prednisone in Adult Healthy Volunteers
115697 Completed A Phase I, open label, randomized, two cohort, two period, oneway study to evaluate the effect of Boceprevir and Telaprevir onDolutegravir pharmacokinetics in healthy adult subjects (ING115697)
115698 Completed A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD with Dolutegravir (GSK1349572) 50 mg twice daily in Opiate-Dependent, HIV Seronegative Adult Subjects.
115705 Completed A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects. Study Listed on
115707 Completed An Open-label, Randomized, Single Dose, Four-Period Crossover study to compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) with 10% and 15% of enteric coated pellets with Harnal-D tablets and Harnal capsules co-administered with dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian ancestry Study Listed on
115708 Completed An Open-label, Randomized, Single Dose, Multi-stage, Cross-over study to determine the Relative bioavailability of Fixed Dose Combination Products containing a 3-oblong dutasteride soft gel capsule and tamsulosin (0.5 mg dutasteride /0.2 mg tamsulosin HCl) pellets having a range of tamsulosin release rates produced by different mixtures of enteric coated and uncoated pellets relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian ancestry. Study Listed on
115711 Completed Phase 1, Open Label Study to Evaluate the Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
115717 Completed A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency Study Listed on
115719 Completed A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 Study Listed on
115720 Completed A Double-Blind, 3-Part Crossover Study to Assess the Pharmacokinetics and Tolerability of Single Doses of Gabapentin Enacarbil and Morphine Administered Alone and in Combination in Healthy Subjects
115730 Completed PGx423 Pharmacogenetic evaluation of efficacy of lapatinib in EGF104900, EGF20009, EGF105084 and VEG20007
115733 Completed WEUKBRE5554: IMI PROTECT (Work Package 2): Use of long acting beta2 adrenoceptor agonists and Acute Myocardial Infarction (AMI)
115734 Completed IMI PROTECT (Work Package 2): Use of antidepressants and risk of hip and/or hip/femur fracture
115736 Completed IMI PROTECT (Work Package 2): Calcium Channel Blocker Treatments and Cancer Risk
115737 Completed WEUKBRE5557: IMI PROTECT (Work Package 2): Use of antiepileptics and risk of suicidality



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.